Fundz

Fundz Deep Dive

Everything you need to win Summit Therapeutics — in one platform.

Who to reach, what to say, and why now on Summit Therapeutics — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Summit Therapeutics — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Summit Therapeutics and AstraZeneca Engage in $15 Billion Partnership Talks for Lung-Cancer Drug Licensing.

Jul 03, 2025•12 months ago

Contract Type

partnership

MiamiBiotechnologyHealth CareTherapeutics

Description

Summit Therapeutics Inc. is currently in discussions with AstraZeneca Plc regarding a significant partnership deal that could see AstraZeneca paying up to $15 billion for licensing rights to Summit's lung-cancer drug, ivonescimab. This partnership aims to enhance treatment options for lung cancer patients and reflects ongoing talks with other pharmaceutical companies as well.

Company Information

Company

Summit Therapeutics

Location

Miami, Florida, United States

About

Summit Therapeutics’ mission is to resolve serious, unmet medical needs for the betterment of overall human health.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Summit Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.